New drug indication approval - July 2021

Product Name

BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML

Active Ingredient

Avelumab

Product Registrant

MERCK PTE. LTD

Date of Approval

01/07/2021

Indications:

Bavencio is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.